Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Other Accumulated Expenses: 2019-2024

Historic Other Accumulated Expenses for Revolution Medicines (RVMD) over the last 6 years, with Dec 2024 value amounting to $583,000.

  • Revolution Medicines' Other Accumulated Expenses rose 544.84% to $8.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.2 million, marking a year-over-year increase of 544.84%. This contributed to the annual value of $583,000 for FY2024, which is 85.04% down from last year.
  • As of FY2024, Revolution Medicines' Other Accumulated Expenses stood at $583,000, which was down 85.04% from $3.9 million recorded in FY2023.
  • Revolution Medicines' 5-year Other Accumulated Expenses high stood at $3.9 million for FY2023, and its period low was $97,000 during FY2020.
  • Its 3-year average for Other Accumulated Expenses is $1.7 million, with a median of $583,000 in 2024.
  • Per our database at Business Quant, Revolution Medicines' Other Accumulated Expenses crashed by 90.74% in 2020 and then surged by 671.49% in 2023.
  • Over the past 5 years, Revolution Medicines' Other Accumulated Expenses (Yearly) stood at $97,000 in 2020, then soared by 220.62% to $311,000 in 2021, then skyrocketed by 62.38% to $505,000 in 2022, then spiked by 671.49% to $3.9 million in 2023, then slumped by 85.04% to $583,000 in 2024.